Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Black Diamond Therapeutics Inc

Current price
5.26 USD +0.09 USD (+1.74%)
Last closed 5.3 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 271 001 248 USD
Yield for 12 month +239.35 %
21.11.2021 - 28.11.2021

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: One Main Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

12.8 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-437 000 USD

Last Year

-3 238 000 USD

Current Quarter

-86 000 USD

Last Quarter

-823 000 USD

Key Figures BDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -86 023 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -34.33 %
PEG Ratio
Return On Equity TTM -70.94 %
Wall Street Target Price 12.8 USD
Revenue TTM
Book Value 2.26 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -1.88 USD
Diluted Eps TTM -1.88 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BDTX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -1.9169
Price Book MRQ 2.3215

Financials BDTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BDTX

For 52 weeks

1.43 USD 6.85 USD
50 Day MA 4.72 USD
Shares Short Prior Month 1 812 637
200 Day MA 3.46 USD
Short Ratio 3.76
Shares Short 2 044 244
Short Percent 6.29 %

Dynamics of changes in the value of assets




399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds



207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics



2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics